Literature DB >> 7933121

Epstein-Barr virus latency in blood mononuclear cells: analysis of viral gene transcription during primary infection and in the carrier state.

R J Tierney1, N Steven, L S Young, A B Rickinson.   

Abstract

Epstein-Barr virus (EBV) can display different forms of latent infection in B-cell lines in vitro; however, the types of infection normally established by the virus in vivo remain largely unexplored. Here we have approached this question by analyzing the types of viral RNAs present in mononuclear cells freshly isolated from the blood of 14 infectious mononucleosis patients undergoing primary EBV infection and 6 long-term virus carriers. Reverse transcription-PCR amplifications were carried out with a panel of oligonucleotide primers and probes which specifically detect (i) the EBER1 RNA common to all forms of latency, (ii) transcripts either from the Cp and Wp promoters generating all six nuclear antigen (EBNA1, -2, -3A, -3B, -3C, -LP) mRNAs or from the Fp promoter generating a uniquely spliced EBNA1 mRNA, (iii) the latent membrane protein (LMP1 and 2A) mRNAs, and (iv) the BZLF1 mRNA, an immediate-early marker of lytic cycle. Viral transcription in infectious mononucleosis mononuclear cells (and in the B-cell-enriched fraction) regularly included the full spectrum of latent RNAs seen during EBV-induced B-cell growth transformation in vitro, i.e., EBER1, Cp/Wp-initiated EBNA mRNAs, and LMP1/LMP2 mRNAs, in the absence of lytic BZLF1 transcripts. In addition, transcripts with the splice pattern of Fp-initiated EBNA1 mRNA, hitherto seen only in vivo in certain EBV-positive tumors, were frequently detected. In long-term virus carriers, the mononuclear cells were again positive for latent (EBER1) and negative for lytic (BZLF1) markers; Cp/Wp-initiated RNAs were not detected in these samples, but in several individuals it was possible to amplify both Fp-initiated EBNA1 mRNA and LMP2A mRNA signals. We suggest (i) that primary infection is associated with a transient virus-driven expansion of the infected B-cell pool through a program of virus gene expression like that seen in in vitro-transformed cells and (ii) that long-term virus carriage is associated with a switch from Cp/Wp to Fp usage and thus to a more restricted form of latent protein expression that may render the infected cells less susceptible to recognition by the virus-specific cytotoxic T-cell response.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 7933121      PMCID: PMC237180     

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  52 in total

1.  Simultaneous presence of EBNA-positive and colony-forming cells in peripheral blood of patients with infectious mononucleosis.

Authors:  T Katsuki; Y Hinuma; T Saito; J Yamamoto; Y Hirashima; H Sudoh; M Deguchi; M Motokawa
Journal:  Int J Cancer       Date:  1979-06-15       Impact factor: 7.396

2.  Absence of infectious Epstein-Barr virus in blood in acute infectious mononucleosis.

Authors:  A B Rickinson; M A Epstein; D H Crawford
Journal:  Nature       Date:  1975-11-20       Impact factor: 49.962

3.  Mechanism of the establishment of Epstein-Barr virus genome-containing lymphoid cell lines from infectious mononucleosis patients: studies with phosphonoacetate.

Authors:  A B Rickinson; S Finerty; M A Epstein
Journal:  Int J Cancer       Date:  1977-12-15       Impact factor: 7.396

4.  Long-term T-cell-mediated immunity to Epstein-Barr virus in man. I. Complete regression of virus-induced transformation in cultures of seropositive donor leukocytes.

Authors:  D J Moss; A B Rickinson; J H Pope
Journal:  Int J Cancer       Date:  1978-12       Impact factor: 7.396

5.  The establishment of lymphoblastoid lines from adult and fetal human lymphoid tissue and its dependence on EBV.

Authors:  K Nilsson; G Klein; W Henle; G Henle
Journal:  Int J Cancer       Date:  1971-11-15       Impact factor: 7.396

6.  EBV-determined nuclear antigen (EBNA)-positive cells in the peripheral blood of infectious mononucleosis patients.

Authors:  G Klein; E Svedmyr; M Jondal; P O Persson
Journal:  Int J Cancer       Date:  1976-01-15       Impact factor: 7.396

7.  Localization of Epstein-Barr virus-encoded small RNAs by in situ hybridization.

Authors:  J G Howe; J A Steitz
Journal:  Proc Natl Acad Sci U S A       Date:  1986-12       Impact factor: 11.205

8.  Long-term T-cell-mediated immunity to Epstein-Barr virus in man. IV. Development of T-cell memory in convalescent infectious mononucleosis patients.

Authors:  A B Rickinson; D J Moss; J H Pope; N Ahlberg
Journal:  Int J Cancer       Date:  1980-01-15       Impact factor: 7.396

9.  Quantitative evaluation of Epstein-Barr-virus-infected mononuclear peripheral blood leukocytes in infectious mononucleosis.

Authors:  G Rocchi; A Felici; G Ragona; A Heinz
Journal:  N Engl J Med       Date:  1977-01-20       Impact factor: 91.245

10.  Two small RNAs encoded by Epstein-Barr virus and complexed with protein are precipitated by antibodies from patients with systemic lupus erythematosus.

Authors:  M R Lerner; N C Andrews; G Miller; J A Steitz
Journal:  Proc Natl Acad Sci U S A       Date:  1981-02       Impact factor: 11.205

View more
  161 in total

1.  Requirement for cell-to-cell contact in Epstein-Barr virus infection of nasopharyngeal carcinoma cells and keratinocytes.

Authors:  Y Chang; C H Tung; Y T Huang; J Lu; J Y Chen; C H Tsai
Journal:  J Virol       Date:  1999-10       Impact factor: 5.103

2.  Inhibition of antigen presentation by the glycine/alanine repeat domain is not conserved in simian homologues of Epstein-Barr virus nuclear antigen 1.

Authors:  N W Blake; A Moghaddam; P Rao; A Kaur; R Glickman; Y G Cho; A Marchini; T Haigh; R P Johnson; A B Rickinson; F Wang
Journal:  J Virol       Date:  1999-09       Impact factor: 5.103

3.  The Epstein-Barr virus latency BamHI-Q promoter is positively regulated by STATs and Zta interference with JAK/STAT activation leads to loss of BamHI-Q promoter activity.

Authors:  H Chen; J M Lee; Y Wang; D P Huang; R F Ambinder; S D Hayward
Journal:  Proc Natl Acad Sci U S A       Date:  1999-08-03       Impact factor: 11.205

Review 4.  The role of EBV in post-transplant malignancies: a review.

Authors:  P Hopwood; D H Crawford
Journal:  J Clin Pathol       Date:  2000-04       Impact factor: 3.411

5.  Sequence variations of Epstein-Barr virus LMP2A gene in gastric carcinoma in Japan.

Authors:  M Tanaka; Y Kawaguchi; J Yokofujita; M Takagi; Y Eishi; K Hirai
Journal:  Virus Genes       Date:  1999       Impact factor: 2.332

6.  Expression of EBNA-1 mRNA is regulated by cell cycle during Epstein-Barr virus type I latency.

Authors:  M G Davenport; J S Pagano
Journal:  J Virol       Date:  1999-04       Impact factor: 5.103

7.  Interferon regulatory factor 2 represses the Epstein-Barr virus BamHI Q latency promoter in type III latency.

Authors:  L Zhang; J S Pagano
Journal:  Mol Cell Biol       Date:  1999-04       Impact factor: 4.272

Review 8.  Epstein-Barr virus infection in the pathogenesis of nasopharyngeal carcinoma.

Authors:  G Niedobitek
Journal:  Mol Pathol       Date:  2000-10

9.  CD8(+) T-cell selection, function, and death in the primary immune response in vivo.

Authors:  M F Callan; C Fazou; H Yang; T Rostron; K Poon; C Hatton; A J McMichael
Journal:  J Clin Invest       Date:  2000-11       Impact factor: 14.808

10.  Cells expressing the Epstein-Barr virus growth program are present in and restricted to the naive B-cell subset of healthy tonsils.

Authors:  A M Joseph; G J Babcock; D A Thorley-Lawson
Journal:  J Virol       Date:  2000-11       Impact factor: 5.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.